Form 4: SOPHIA GENETICS SA: Insider Sells Shares

SOPHIA GENETICS SA reports a Form 4 filing detailing a transaction by Chief Medical Officer Philippe Menu.

Summary

• Philippe Menu, Chief Medical Officer of SOPHiA GENETICS SA, sold 5,000 ordinary shares.
• The transaction occurred on June 25, 2026, under a Rule 10b5-1(c) trading plan.
• The weighted average sale price was $5.50, with individual sales ranging from $5.30 to $5.69.
• Following the transaction, Mr. Menu beneficially owns 240,780 ordinary shares.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as the transaction was conducted under a pre-established trading plan, indicating it was likely pre-scheduled and not a reaction to new information.

Negatives

• Insider selling of shares can sometimes be interpreted negatively by the market, though this sale was conducted under a pre-arranged trading plan.

Future Outlook

No specific future outlook or guidance is provided in this filing.

Industry Context

StockSavvy.ai notes that insider transactions, particularly under Rule 10b5-1(c) plans, are common for executives to manage personal finances while adhering to trading regulations. The significance of this particular sale depends on the executive's overall holdings and prior trading activity.

Stakeholder Impact

• Shareholders: The sale of shares by an executive may lead to short-term market scrutiny, but the pre-arranged nature of the trade under Rule 10b5-1(c) mitigates concerns about insider trading based on material non-public information.

Key Dates

Keywords

SOPHiA GENETICS SA, Form 4, Insider Trading, Share Sale, Philippe Menu, Rule 10b5-1(c)